Vybrant™ Cell Metabolic Assay Kit, with C12-resazurin
Vybrant&trade; Cell Metabolic Assay Kit, with C<sub>12</sub>-resazurin
Citations & References (7)
Invitrogen™

Vybrant™ Cell Metabolic Assay Kit, with C12-resazurin

Vybrant™代謝細胞アッセイキットでは、生細胞によって非蛍光性のC12-レサズリンが蛍光性C12-レゾルフィンに還元されます。得られたシグナルは、存在する細胞数に比例します。C12-レサズリンはalamarBlue™色素よりも細胞保持力が高く、生存率インジケーターやその他のバイオマーカーと多重化できます。詳細を見る
テクニカルサポートオーダーサポート
製品番号（カタログ番号）数量
V231101 kit
製品番号（カタログ番号） V23110
価格（JPY）
80,600
1 kit
お問い合わせください ›
数量:
1 kit
Vybrant™代謝細胞アッセイキットでは、生細胞によって非蛍光性のC12-レサズリンが蛍光性C12-レゾルフィンに還元されます。得られたシグナルは、存在する細胞数に比例します。C12-レサズリンはalamarBlue™色素よりも細胞保持力が高く、生存率インジケーターやその他のバイオマーカーと多重化できます。
研究用にのみ使用できます。診断用には使用いただけません。
仕様
検出法蛍光
染色剤タイプレゾルフィン
フォーマットチューブ、96ウェルプレート
数量1 kit
出荷条件室温
使用対象（アプリケーション）細胞代謝アッセイ
使用対象 (装置)フローサイトメーター, マイクロプレートリーダー
製品ラインVybrant
製品タイプ色素
Unit Size1 kit
組成および保存条件
フリーザー（-5℃～-30℃）に保存し、遮光してください。

よくあるご質問（FAQ）

How do alamarBlue reagent and PrestoBlue reagent differ from resazurin and C12-resazurin?

alamarBlue reagent and PrestoBlue reagent contain resazurin in a proprietary stabilizing formulation that allows for a convenient “mix, incubate, and read” protocol. PrestoBlue reagent is an improvement in the formulation of alamarBlue reagent that allows for much faster staining (typically 10 minutes vs. 1-4 hours to obtain a similar signal and sensitivity). C12-resazurin is a derivative of resazurin that has better cellular retention and thus allows for analysis on a flow cytometer and multiplexing with viability indicators and other biomarkers.

Find additional tips, troubleshooting help, and resources within our Cell Analysis Support Center.

What is the absorbance/emission of the reaction product from the Vybrant Cell Metabolic Assay Kit?

The absorbance/emission is 563/587 nm.

Find additional tips, troubleshooting help, and resources within our Cell Analysis Support Center.

引用および参考文献 (7)

引用および参考文献
Abstract
Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus.
Authors:Parsons JB, Yao J, Frank MW, Jackson P, Rock CO,
Journal:J Bacteriol
PubMed ID:22843840
The skin represents an important barrier for pathogens and is known to produce fatty acids that are toxic toward gram-positive bacteria. A screen of fatty acids as growth inhibitors of Staphylococcus aureus revealed structure-specific antibacterial activity. Fatty acids like oleate (18:1?9) were nontoxic, whereas palmitoleate (16:1?9) was a potent growth ... More
Perturbational profiling of nanomaterial biologic activity.
Authors:Shaw SY, Westly EC, Pittet MJ, Subramanian A, Schreiber SL, Weissleder R,
Journal:Proc Natl Acad Sci U S A
PubMed ID:18492802
'Our understanding of the biologic effects (including toxicity) of nanomaterials is incomplete. In vivo animal studies remain the gold standard; however, widespread testing remains impractical, and the development of in vitro assays that correlate with in vivo activity has proven challenging. Here, we demonstrate the feasibility of analyzing in vitro ... More
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
Authors:Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH,
Journal:Cancer Res
PubMed ID:18922911
'Multivalent antibodies, either monospecific or bispecific, may improve the efficacy of current therapeutic interventions involving a single monoclonal antibody (mAb). We have applied the Dock-and-Lock (DNL) method, a new platform technology for the site-specific and covalent assembly of modular components into stably tethered complexes of defined composition, to prepare a ... More
Preclinical studies on targeted delivery of multiple IFNa2b to HLA-DR in diverse hematologic cancers.
Authors:Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH,
Journal:Blood
PubMed ID:21680794
The short circulating half-life and side effects of IFNa affect its dosing schedule and efficacy. Fusion of IFNa to a tumor-targeting mAb (mAb-IFNa) can enhance potency because of increased tumor localization and improved pharmacokinetics. We used the Dock-and-Lock method to generate C2-2b-2b, a mAb-IFNa comprising tetrameric IFNa2b site-specifically linked to ... More
Hypothermia reduces secretion of vascular endothelial growth factor by cultured retinal pigment epithelial cells.
Authors:Coassin M, Duncan KG, Bailey KR, Singh A, Schwartz DM,
Journal:Br J Ophthalmol
PubMed ID:20805126
Visual loss in age-related macular degeneration usually develops secondary to choroidal neovascularisation. Vascular endothelial growth factor (VEGF) is a critical regulator of retinal angiogenesis and vascular permeability, especially in hypoxic conditions. We hypothesise that hypothermia may reduce the retinal pigment epithelium (RPE) metabolism and, consequently, the levels of VEGF secretion ... More
View all Vybrant™ Cell Metabolic Assay Kit, with C12-resazurin citations